Emerald Advisers LLC Has $13.32 Million Position in Collegium Pharmaceutical, Inc. $COLL

Emerald Advisers LLC lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 36.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 402,752 shares of the specialty pharmaceutical company’s stock after selling 226,592 shares during the quarter. Emerald Advisers LLC’s holdings in Collegium Pharmaceutical were worth $13,319,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Fifth Third Bancorp lifted its stake in shares of Collegium Pharmaceutical by 16,152.5% in the first quarter. Fifth Third Bancorp now owns 29,092 shares of the specialty pharmaceutical company’s stock valued at $962,000 after buying an additional 28,913 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Collegium Pharmaceutical during the first quarter valued at about $686,000. James Investment Research Inc. increased its position in shares of Collegium Pharmaceutical by 19.7% during the first quarter. James Investment Research Inc. now owns 7,110 shares of the specialty pharmaceutical company’s stock worth $235,000 after acquiring an additional 1,170 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical during the first quarter worth about $3,185,000. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth about $463,000.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $34.82 on Tuesday. The firm has a 50-day moving average of $34.71 and a 200-day moving average of $38.64. The company has a market cap of $1.13 billion, a P/E ratio of 17.07 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical, Inc. has a one year low of $29.19 and a one year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period last year, the firm earned $1.49 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on COLL. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.